NASDAQ:BVS

Bioventus (BVS) Stock Price, News & Analysis

Bioventus logo
$9.88 -0.07 (-0.70%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$9.90 +0.01 (+0.15%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Bioventus Stock (NASDAQ:BVS)

Advanced

Key Stats

Today's Range
$9.81
▼
$10.17
50-Day Range
$9.88
▼
$15.04
52-Week Range
$6.47
▼
$15.89
Volume
612,434 shs
Average Volume
701,226 shs
Market Capitalization
$832.49 million
P/E Ratio
12.35
Dividend Yield
N/A
Price Target
$16.60
Consensus Rating
Moderate Buy

Company Overview

Bioventus Inc. is a medical technology company focused on helping patients recover from musculoskeletal conditions and injuries. Its products and services support bone healing, pain management and surgical care.

The company’s offerings include noninvasive devices that use ultrasound to support bone healing, injectable treatments for osteoarthritis pain, and surgical products such as bone graft materials and ultrasonic instruments used in procedures.

Bioventus began operations in 2012, originating from businesses previously owned by Smith & Nephew. It serves healthcare providers and patients in the United States and international markets.

AI Generated. May Contain Errors.

Bioventus Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

BVS MarketRank™: 
3.81032547699 of 5 stars

Bioventus scored higher than 76% of companies evaluated by MarketBeat, and ranked 120th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bioventus has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    Bioventus has a consensus price target of $16.60, representing about 68.0% upside from its current price of $9.88.

  • Amount of Analyst Coverage

    Bioventus has only been the subject of 2 research reports in the past 90 days.

  • Read more about Bioventus' stock forecast and price target.
  • Earnings Growth

    Earnings for Bioventus are expected to grow by 12.82% in the coming year, from $0.78 to $0.88 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bioventus is 12.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.19.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bioventus is 12.35, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.56.

  • Price to Earnings Growth Ratio

    Bioventus has a PEG Ratio of 1.27. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Bioventus has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.39% of the float of Bioventus has been sold short.
  • Short Interest Ratio / Days to Cover

    Bioventus has a short interest ratio ("days to cover") of 6.62.
  • Change versus previous month

    Short interest in Bioventus has recently decreased by 4.88%, indicating that investor sentiment is improving.
  • Dividend Yield

    Bioventus does not currently pay a dividend.

  • Dividend Growth

    Bioventus does not have a long track record of dividend growth.

  • News Sentiment

    Bioventus has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Bioventus this week, compared to 2 articles on an average week.
  • Search Interest

    Only 3 people have searched for BVS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Bioventus to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bioventus insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    33.50% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bioventus' insider trading history.
Receive BVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BVS Stock News Headlines

Bioventus Earnings Call Highlights Growth Amid Headwinds
Seven bucks, yours for life: my Black Friday indicator deal
Base Camp Trading's Thomas Wood is giving away his proprietary Snapback Indicator for just $7 this Black Friday. Others paid $500 for it. It's a one-time price with no recurring billing, and the indicator is yours for life. It shows when it's time to sell or go short, and when it makes sense to buy. Check it for a potential Snapback before your next trade.tc pixel
Bioventus (BVS) Q3 2026 Earnings Call Transcript
See More Headlines

BVS Stock Analysis - Frequently Asked Questions

Bioventus' stock was trading at $7.44 at the start of the year. Since then, BVS stock has increased by 32.8% and is now trading at $9.88.

Bioventus Inc. (NASDAQ:BVS) announced its earnings results on Monday, November, 2nd. The company reported $0.17 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.17. The firm earned $142.44 million during the quarter. Bioventus had a net margin of 9.78% and a trailing twelve-month return on equity of 26.31%.
Read the conference call transcript
.

Bioventus (BVS) raised $136 million in an initial public offering on Thursday, February 11th 2021. The company issued 8,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO.

Bioventus' top institutional investors include Nantahala Capital Management LLC (7.62%), American Century Companies Inc. (2.57%), Royce & Associates LP (1.91%) and State Street Corp (1.39%). Insiders that own company stock include John A Bartholdson, Mark Leonard Singleton, Anthony D'adamio, Guy P Nohra, Robert E Claypoole, Katrina J Church and Michelle Mcmurry-Heath.
View institutional ownership trends
.

Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioventus investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Tesla (TSLA), Alibaba Group (BABA), Intel (INTC), Micron Technology (MU) and Walt Disney (DIS).

Company Calendar

Last Earnings
11/02/2026
Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:BVS
Previous Symbol
NASDAQ:BVS
CIK
1665988
Fax
N/A
Employees
960
Year Founded
2012

Price Target and Rating

High Price Target
$18.00
Low Price Target
$14.00
Potential Upside/Downside
+68.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.80
Trailing P/E Ratio
12.35
Forward P/E Ratio
11.23
P/E Growth
1.27
Net Income
$22.73 million
Net Margins
9.78%
Pretax Margin
6.85%
Return on Equity
26.31%
Return on Assets
10.13%

Debt

Debt-to-Equity Ratio
0.72
Current Ratio
1.68
Quick Ratio
1.16

Sales & Book Value

Annual Sales
$568.09 million
Price / Sales
1.47
Cash Flow
$1.27 per share
Price / Cash Flow
7.75
Book Value
$3.46 per share
Price / Book
2.86

Miscellaneous

Outstanding Shares
84,260,000
Free Float
56,034,000
Market Cap
$832.49 million
Optionable
Optionable
Beta
0.66

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:BVS) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners